PMID- 33005178
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201003
IS  - 1664-8021 (Print)
IS  - 1664-8021 (Electronic)
IS  - 1664-8021 (Linking)
VI  - 11
DP  - 2020
TI  - Development of an Immune-Related Risk Signature for Predicting Prognosis in Lung 
      Squamous Cell Carcinoma.
PG  - 978
LID - 10.3389/fgene.2020.00978 [doi]
LID - 978
AB  - Lung squamous cell carcinoma (LSCC) is the most common subtype of non-small cell 
      lung cancer. Immunotherapy has become an effective treatment in recent years, 
      while patients showed different responses to the current treatment. It is vital 
      to identify the potential immunogenomic signatures to predict patient' prognosis. 
      The expression profiles of LSCC patients with the clinical information were 
      downloaded from TCGA database. Differentially expressed immune-related genes 
      (IRGs) were extracted using edgeR algorithm, and functional enrichment analysis 
      showed that these IRGs were primarily enriched in inflammatory- and 
      immune-related processes. "Cytokine-cytokine receptor interaction" and "PI3K-AKT 
      signaling pathway" were the most enriched KEGG pathways. 27 differentially 
      expressed IRGs were significantly correlated with the overall survival (OS) of 
      patients using univariate Cox regression analysis. A prognostic risk signature 
      that comprises seven IRGs (GCCR, FGF8, CLEC4M, PTH, SLC10A2, NPPC, and FGF4) was 
      developed with effective predictive performance by multivariable Cox stepwise 
      regression analysis. Most importantly, the signature could be an independent 
      prognostic predictor after adjusting for clinicopathological parameters, and also 
      validated in two independent LSCC cohorts (GSE4573 and GSE17710). Potential 
      molecular mechanisms and tumor immune landscape of these IRGs were investigated 
      through computational biology. Analysis of tumor infiltrating lymphocytes and 
      immune checkpoint molecules revealed distinct immune landscape in high- and 
      low-risk group. The study was the first time to construct IRG-based immune 
      signature in the recognition of disease progression and prognosis of LSCC 
      patients.
CI  - Copyright (c) 2020 Fu, Zhang, Yang, Huang and Xin.
FAU - Fu, Denggang
AU  - Fu D
AD  - School of Basic Medicine, Jiujiang University, Jiujiang, China.
AD  - School of Medicine, Indiana University, Indianapolis, IN, United States.
FAU - Zhang, Biyu
AU  - Zhang B
AD  - School of Pharmacy and Life Science, Jiujiang University, Jiujiang, China.
FAU - Yang, Lei
AU  - Yang L
AD  - School of Basic Medicine, Jiujiang University, Jiujiang, China.
FAU - Huang, Shaoxin
AU  - Huang S
AD  - School of Basic Medicine, Jiujiang University, Jiujiang, China.
FAU - Xin, Wang
AU  - Xin W
AD  - School of Basic Medicine, Jiujiang University, Jiujiang, China.
LA  - eng
PT  - Journal Article
DEP - 20200828
PL  - Switzerland
TA  - Front Genet
JT  - Frontiers in genetics
JID - 101560621
PMC - PMC7485220
OTO - NOTNLM
OT  - immune-related genes
OT  - lung squamous cell carcinoma
OT  - prognosis
OT  - risk score
OT  - signature
EDAT- 2020/10/03 06:00
MHDA- 2020/10/03 06:01
PMCR- 2020/08/28
CRDT- 2020/10/02 05:44
PHST- 2020/04/23 00:00 [received]
PHST- 2020/08/03 00:00 [accepted]
PHST- 2020/10/02 05:44 [entrez]
PHST- 2020/10/03 06:00 [pubmed]
PHST- 2020/10/03 06:01 [medline]
PHST- 2020/08/28 00:00 [pmc-release]
AID - 10.3389/fgene.2020.00978 [doi]
PST - epublish
SO  - Front Genet. 2020 Aug 28;11:978. doi: 10.3389/fgene.2020.00978. eCollection 2020.